BeOne Medicines (NASDAQ:ONC) COO Sells $361,993.32 in Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) COO Xiaobin Wu sold 1,357 shares of the business’s stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $266.76, for a total value of $361,993.32. The sale was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Xiaobin Wu also recently made the following trade(s):

• On Thursday, June 11th, Xiaobin Wu sold 626 shares of BeOne Medicines stock. The shares were sold at an average price of $261.20, for a total transaction of $163,511.20.
• On Monday, June 8th, Xiaobin Wu sold 1,484 shares of BeOne Medicines stock. The stock was sold at an average price of $269.37, for a total transaction of $399,745.08.

BeOne Medicines Price Performance

Shares of NASDAQ:ONC opened at $270.15 on Friday. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27. The stock has a market cap of $29.64 billion, a price-to-earnings ratio of 60.44 and a beta of 0.49. The company has a 50 day moving average of $295.32 and a 200-day moving average of $312.15. BeOne Medicines Ltd. – Sponsored ADR has a one year low of $239.25 and a one year high of $385.22.

BeOne Medicines (NASDAQ:ONC) last announced its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. The business had revenue of $1.51 billion for the quarter. On average, sell-side analysts forecast that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. EFG International AG bought a new stake in BeOne Medicines in the fourth quarter valued at approximately $25,000. Leonteq Securities AG acquired a new stake in BeOne Medicines in the fourth quarter worth $35,000. Daiwa Securities Group Inc. bought a new position in shares of BeOne Medicines during the second quarter worth $35,000. CWM LLC boosted its position in shares of BeOne Medicines by 32.8% during the fourth quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after purchasing an additional 39 shares in the last quarter. Finally, Group One Trading LLC acquired a new position in shares of BeOne Medicines in the 4th quarter valued at $61,000. Institutional investors and hedge funds own 48.55% of the company’s stock.

Wall Street Analyst Weigh In

ONC has been the subject of several recent research reports. Wolfe Research began coverage on shares of BeOne Medicines in a research report on Friday, March 27th. They set an “outperform” rating and a $340.00 target price for the company. Leerink Partners raised their price target on BeOne Medicines from $364.00 to $367.00 and gave the stock an “outperform” rating in a research report on Friday, May 15th. Wall Street Zen cut BeOne Medicines from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Royal Bank Of Canada upped their price objective on BeOne Medicines from $425.00 to $436.00 and gave the company an “outperform” rating in a report on Tuesday, June 2nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a research note on Monday, April 20th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $390.00.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.